Implications for pharmaceutical and medical device
Pharmaceutical and medical device companies selling products
manufactured abroad could find competing in the Turkish market more
difficult in the near future.
What the Action Plan says
Turkey has long suffered from a high current account deficit, a
significant cause of which is the import of medicines. According to
the Action Plan, to incentivize local manufacturing, the Turkish
develop strategies for the pharmaceutical and medical device
establish a Health Industries Orientation Committee and a
Health Institutes Authority;
introduce financial incentives for public healthcare
institutions to procure locally-manufactured products;
prioritize locally-manufactured products through licensing,
pricing and reimbursement procedures;
favor export products in reimbursement applications;
introduce incentives for researchers to participate in clinical
introduce incentives for R&D and clinical trials;
develop technical and legal infrastructure for orphan
improve the legal and regulatory environment for off-set and
local manufacturing, particularly for biotech products;
introduce incentives for investments in Class II and Class III
medical products and biotech medicines;
seek bilateral agreements with other countries to facilitate
the marketing authorization process for products manufactured in
promote the Turkish healthcare industry abroad.
Actions to consider
Pharmaceutical and medical device companies should:
consider whether manufacturing their products in Turkey would
be necessary to maintain competitive strength in the Turkish
closely follow off-set opportunities, local manufacturing
incentives and changes to Turkish pharmaceutical and medical device
regulations in Turkey.
Additionally, pharmaceutical companies and clinical trial
contract research organizations should closely follow the
development of clinical trial incentives in Turkey.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
Inquests are something which affect a vast range of NHS and private organisations, as well as individual clinicians, and so we provide a brief overview of recent developments as well as a couple of key potential changes to come.
Le 28 janvier dernier, le Président du Tribunal de grande instance de Nanterre, statuant en référé, a accordé des dommages et intérêts au titre du préjudice d'anxiété à certaines victimes du Mediator dans trois jugements.
The Turkish Competition Board has launched an investigation into the alleged blocking by the Turkish Pharmacists Union of "named patient sales" by pharmaceutical warehouses.
Some comments from our readers… “The articles are extremely timely and highly applicable” “I often find critical information not available elsewhere” “As in-house counsel, Mondaq’s service is of great value”
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).